Using exosomes to switch myeloid cells

Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer

Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer.

The biotech presented preclinical data Nov. 18 at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy showing that ASO-carrying exosome therapies can be an

Read the full 544 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers